Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Net Income towards Common Stockholders (2016 - 2025)

Ani Pharmaceuticals' Net Income towards Common Stockholders history spans 15 years, with the latest figure at $27.5 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 357.35% year-over-year to $27.5 million; the TTM value through Dec 2025 reached $77.2 million, up 483.08%, while the annual FY2025 figure was $77.2 million, 483.08% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was $27.5 million at Ani Pharmaceuticals, up from $26.3 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $27.5 million in Q4 2025 and bottomed at -$24.6 million in Q3 2024.
  • The 5-year median for Net Income towards Common Stockholders is -$1.3 million (2021), against an average of -$908850.0.
  • The largest annual shift saw Net Income towards Common Stockholders tumbled 25451.85% in 2022 before it soared 1623.23% in 2024.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$24.3 million in 2021, then surged by 80.89% to -$4.6 million in 2022, then skyrocketed by 116.11% to $749000.0 in 2023, then plummeted by 1526.17% to -$10.7 million in 2024, then soared by 357.35% to $27.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Net Income towards Common Stockholders are $27.5 million (Q4 2025), $26.3 million (Q3 2025), and $8.1 million (Q2 2025).